Table 2

Characteristics of pancreatic lesions in IAR (n=134)

ParameterAll IAR with lesions
(n=134)
IAR with lesions at first screening
(n=89)
IAR with lesions during follow-up
(n=45)
Type of lesion:* cystic/solid/indeterminate125/3/683/1/542/2/1
Cystic lesions <10 mm121 (90%)80 (90%)41 (91%)
Cystic lesions >10 mm4 (3%)3 (3.4%)1 (2.2%)
Solid lesions3 (2.2%)1 (1.1%)2 (4.4%)
Indeterminate lesions6 (4.5%)5 (5.6%)1 (2.2%)
IAR with surgery21 (16%)10 (11%)11 (24%)
Potentially relevant histology†15/21 (71%)7/10 (70%)8/11 (73%)
Significant histology‡6/21 (29%)3/10 (30%)3/11 (27%)
  • *As determined by MRI and EUS.

  • †Includes 2 PDAC, PanIN3, IPMN with high-grade dysplasia; multifocal PanIN2±BD-IPMN±AFL, IPMN with low/moderate-grade dysplasia, pNET.

  • ‡Only includes PDAC, PanIN3 and IPMN with high-grade dysplasia.

  • AFL, atypical flat lesion; BD, branch duct; EUS, endoscopic ultrasonography; IAR, individuals at risk; IPMN, intraductal papillary mucinous neoplasia; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET, pancreatic neuroendocrine tumour.